Bioventus Inc.
US ˙ NasdaqGS ˙ US09075A1088

SecurityBVS / Bioventus Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership133,021 shares
Latest Disclosed Value $ 1,214,482
Qube Research & Technologies Ltd reports 70.37% decrease in ownership of BVS / Bioventus Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 133,021 shares of Bioventus Inc. (US:BVS) valued at $1,214,482 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 449,006 shares of Bioventus Inc.. This represents a change in shares of -70.37% during the quarter. The current value of the position is $1,137,330 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BIOVENTUS COM CL A 09075A108 133,021 -315,985 -70.37 1,214 -63.65 0.0014
2026-02-17 2025-12-31 13F BIOVENTUS COM CL A 09075A108 449,006 -76,097 -14.49 3,341 -4.90 0.0034
2025-11-14 2025-09-30 13F BIOVENTUS COM CL A 09075A108 525,103 106,515 25.45 3,513 26.74 0.0036
2025-08-14 2025-06-30 13F BIOVENTUS COM CL A 09075A108 418,588 58,358 16.20 2,771 -15.93 0.0028
2025-05-15 2025-03-31 13F BIOVENTUS COM CL A 09075A108 360,230 106,201 41.81 3,296 23.58 0.0038
2025-02-14 2024-12-31 13F BIOVENTUS COM CL A 09075A108 254,029 108,481 74.53 2,667 53.36 0.0035
2024-11-14 2024-09-30 13F BIOVENTUS COM CL A 09075A108 145,548 -99,459 -40.59 1,739 23.51 0.0026
2024-08-14 2024-06-30 13F BIOVENTUS COM CL A 09075A108 245,007 -46,206 -15.87 1,409 -7.00 0.0022
2024-05-14 2024-03-31 13F BIOVENTUS COM CL A 09075A108 291,213 112,754 63.18 1,514 61.06 0.0024
2024-02-13 2023-12-31 13F BIOVENTUS COM CL A 09075A108 178,459 154,936 658.66 940 1,120.78 0.0018
2023-11-13 2023-09-30 13F BIOVENTUS COM CL A 09075A108 23,523 -67,522 -74.16 78 -70.72 0.0002
2023-08-14 2023-06-30 13F BIOVENTUS COM CL A 09075A108 91,045 91,045 263 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.